Bevacizumab (Nurse)
Medication Basics
Drug Name
Bevacizumab (Brand names: Avastin®, Mvasi®, Zirabev®, Alymsys®, Vegzelma®)
Purpose / Indication
Used to treat several cancers, including colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, ovarian/fallopian tube/primary peritoneal cancer, and hepatocellular carcinoma in selected regimens. Verify indication, regimen, line of therapy, biomarker requirements, and institutional protocol before administration.
Dosage & Administration
Dose Schedule
Administered as an intravenous infusion. Dose and frequency vary by cancer type and regimen, often every 2 or 3 weeks.
Route
IV (Intravenous)
Timing Considerations
Confirm treatment plan, cycle timing, combination agents, hold parameters, infusion duration, and any required pre-infusion assessments before administration.
Time of Day
Flexible
Special Instructions
Assess baseline symptoms, review labs, confirm consent, educate on immune-related or targeted-therapy toxicities, and follow institutional hypersensitivity/infusion reaction procedures.
Injection Techniques
Administer by IV infusion per institutional policy and current prescribing information. Do not administer IV push or bolus unless specifically supported by policy.
Mechanism of Action
Mechanism
Bevacizumab is a VEGF inhibitor that binds VEGF-A and inhibits angiogenesis. Nursing monitoring emphasizes blood pressure, proteinuria, bleeding, thrombosis, wound healing, GI perforation, and infusion tolerance.